Bank of Montreal’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.05M | Sell |
22,318
-63,865
| -74% | -$15M | ﹤0.01% | 1264 |
|
|
2026
Q1 | $17.2M | Sell |
86,183
-39,880
| -32% | -$7.89M | 0.01% | 897 |
|
|
2025
Q4 | $23.8M | Buy |
126,063
+294
| +0.2% | +$56.5K | 0.01% | 793 |
|
|
2025
Q3 | $22.3M | Buy |
125,769
+120,043
| +2,096% | +$17.8M | 0.01% | 737 |
|
|
2025
Q2 | $651K | Buy |
5,726
+147
| +3% | +$15.7K | ﹤0.01% | 2122 |
|
|
2025
Q1 | $587K | Buy |
5,579
+981
| +21% | +$111K | ﹤0.01% | 2102 |
|
|
2024
Q4 | $493K | Buy |
4,598
+226
| +5% | +$25.5K | ﹤0.01% | 2243 |
|
|
2024
Q3 | $426K | Buy |
4,372
+150
| +4% | +$15.1K | ﹤0.01% | 2525 |
|
|
2024
Q2 | $356K | Buy |
4,222
+81
| +2% | +$6.45K | ﹤0.01% | 2624 |
|
|
2024
Q1 | $303K | Buy |
4,141
+192
| +5% | +$14.2K | ﹤0.01% | 2774 |
|
|
2023
Q4 | $290K | Buy |
+3,949
| New | +$233K | ﹤0.01% | 2880 |
|
|
2022
Q2 | – | Sell |
-7,170
| Closed | -$540K | – | 4278 |
|
|
2022
Q1 | $540K | Sell |
7,170
-125
| -2% | -$9.07K | ﹤0.01% | 2774 |
|
|
2021
Q4 | $741K | Sell |
7,295
-2,018
| -22% | -$186K | ﹤0.01% | 2127 |
|
|
2021
Q3 | $821K | Buy |
9,313
+7,117
| +324% | +$550K | ﹤0.01% | 2605 |
|
|
2021
Q2 | $190K | Sell |
2,196
-87
| -4% | -$7.24K | ﹤0.01% | 3225 |
|
|
2021
Q1 | $221K | Sell |
2,283
-2,800
| -55% | -$265K | ﹤0.01% | 3066 |
|
|
2020
Q4 | $346K | Buy |
5,083
+2,275
| +81% | +$130K | ﹤0.01% | 2906 |
|
|
2020
Q3 | $177K | Sell |
2,808
-722
| -20% | -$49.3K | ﹤0.01% | 2792 |
|
|
2020
Q2 | $247K | Buy |
3,530
+2,914
| +473% | +$185K | ﹤0.01% | 2622 |
|
|
2020
Q1 | $28K | Sell |
616
-6,203
| -91% | -$352K | ﹤0.01% | 3117 |
|
|
2019
Q4 | $444K | Buy |
6,819
+3,264
| +92% | +$218K | ﹤0.01% | 2738 |
|
|
2019
Q3 | $221K | Sell |
3,555
-289
| -8% | -$18.1K | ﹤0.01% | 2848 |
|
|
2019
Q2 | $274K | Buy |
3,844
+2,228
| +138% | +$164K | ﹤0.01% | 2754 |
|
|
2019
Q1 | $127K | Sell |
1,616
-14,417
| -90% | -$1.09M | ﹤0.01% | 2954 |
|
|
2018
Q4 | $1.36M | Buy |
16,033
+529
| +3% | +$56.4K | ﹤0.01% | 1737 |
|
|
2018
Q3 | $2.65M | Buy |
15,504
+519
| +3% | +$78.2K | ﹤0.01% | 1526 |
|
|
2018
Q2 | $1.94M | Sell |
14,985
-604
| -4% | -$67.4K | ﹤0.01% | 1657 |
|
|
2018
Q1 | $1.61M | Sell |
15,589
-316
| -2% | -$31.3K | ﹤0.01% | 1666 |
|
|
2017
Q4 | $1.36M | Buy |
15,905
+14,684
| +1,203% | +$1.27M | ﹤0.01% | 1805 |
|
|
2017
Q3 | $103K | Sell |
1,221
-8,025
| -87% | -$635K | ﹤0.01% | 2973 |
|
|
2017
Q2 | $700K | Sell |
9,246
-60,776
| -87% | -$4.25M | ﹤0.01% | 2139 |
|
|
2017
Q1 | $4.62M | Buy |
70,022
+34,064
| +95% | +$2.24M | ﹤0.01% | 1107 |
|
|
2016
Q4 | $2.34M | Sell |
35,958
-124,845
| -78% | -$7.88M | ﹤0.01% | 1465 |
|
|
2016
Q3 | $10.2M | Buy |
160,803
+156,754
| +3,871% | +$11.5M | 0.01% | 804 |
|
|
2016
Q2 | $301K | Sell |
4,049
-6,539
| -62% | -$485K | ﹤0.01% | 2282 |
|
|
2016
Q1 | $707K | Buy |
10,588
+354
| +3% | +$21.5K | ﹤0.01% | 1899 |
|
|
2015
Q4 | $692K | Buy |
10,234
+403
| +4% | +$24.9K | ﹤0.01% | 1866 |
|
|
2015
Q3 | $525K | Sell |
9,831
-789
| -7% | -$47.9K | ﹤0.01% | 1833 |
|
|
2015
Q2 | $668K | Buy |
10,620
+3,645
| +52% | +$199K | ﹤0.01% | 1835 |
|
|
2015
Q1 | $336K | Sell |
6,975
-473
| -6% | -$18.1K | ﹤0.01% | 2134 |
|
|
2014
Q4 | $247K | Sell |
7,448
-961
| -11% | -$31.3K | ﹤0.01% | 2389 |
|
|
2014
Q3 | $246K | Buy |
8,409
+6,077
| +261% | +$202K | ﹤0.01% | 2435 |
|
|
2014
Q2 | $90K | Buy |
2,332
+721
| +45% | +$29.3K | ﹤0.01% | 2911 |
|
|
2014
Q1 | $67K | Buy |
1,611
+1,162
| +259% | +$48.4K | ﹤0.01% | 2988 |
|
|
2013
Q4 | $15K | Sell |
449
-1,768
| -80% | -$57.6K | ﹤0.01% | 3305 |
|
|
2013
Q3 | $60K | Hold |
2,217
| – | – | ﹤0.01% | 2733 |
|
|
2013
Q2 | $52K | Buy |
+2,217
| New | +$39.9K | ﹤0.01% | 2701 |
|
Other funds holding LGND
VPM
VCM
CAM
CC
SIMG
Bank of Montreal's LGND Position: Q2 2026 in Review
Bank of Montreal reduced its Ligand Pharmaceuticals (LGND) stake by 74% in Q2 2026, selling an estimated $15M and leaving 22,318 shares worth $7.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1264.
Bank of Montreal first reported a position in LGND in Q2 2013 and has held it in 47 quarters since. The position peaked at $23.8M in Q4 2025. 331 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Bank of Montreal held 22,318 shares of Ligand Pharmaceuticals worth $7.05M as of Q2 2026.
- Bank of Montreal sold 63,865 Ligand Pharmaceuticals shares in Q2 2026, an estimated $15M.
- Ligand Pharmaceuticals made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #1264 holding.
- Bank of Montreal first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
- Bank of Montreal's Ligand Pharmaceuticals position peaked at $23.8M in Q4 2025.
- 331 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.